Accelerate biotechnology

Menzo Havenga wins CEO Today Healthcare Award 2019

We are proud to announce that our CEO, Menzo Havenga, has won the CEO Today Healthcare Award 2019. Menzo is praised for his leading role in the biopharmaceutical medicines development sector and his strive to ensure biopharmaceuticals are affordable and available for all in need. In an interview with CEO Today Magazine, Menzo Havenga commented:…


Batavia Biosciences to manufacture Marburg vaccine for IAVI under $35.7M DTRA grant

Leiden, the Netherlands, Nov 12, 2019 – We are proud to announce that we have partnered with IAVI under an award they have received from the US Defense Threat Reduction Agency (DTRA) to develop a VSV-based vaccine against Marburg virus. (Link to IAVI press release) This is the second collaboration between Batavia and IAVI on VSV…


National winner in European Business Awards for 3rd consecutive year

Batavia Biosciences has once again been selected as National Winner in the award category ‘Innovation’ in The European Business Awards, Europe’s largest business competition. The award to Batavia was granted by a panel of independent judges including senior business leaders, politicians and academics during a fierce competition involving 98 Dutch nominated companies. Menzo Havenga, CEO…


$6.5M grant to take next step towards polio-free world

Leiden, the Netherlands, Sep 16, 2019 – Today, Batavia Biosciences announces it received a grant of $6.5 million from the Bill & Melinda Gates Foundation to develop a manufacturing process for a novel oral vaccine against polio virus type 2 strain (nOPV2) to help protect children worldwide from future polio outbreaks. In a collaboration with…


Batavia Biosciences to deploy Horizon Discovery’s CHO cell technology to develop anti-Zika biotherapeutic with Vanderbilt University Medical Center and IDBiologics

Leiden, 3 September 2019 – Today, Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines. Initially, Batavia will deploy the system for production of a potent Zika virus neutralizing antibody, working in…


$2.2 million follow-up grant from PATH to support new tools for polio eradication era

Leiden, 4 Jul 2019 – Today, Batavia Biosciences announces it received a follow-up grant of $2.2 million from PATH – a global organization dedicated to health equity – to develop and manufacture novel oral poliovirus vaccines (nOPV). The project, which is funded by the Bill & Melinda Gates Foundation, aims to protect children worldwide from…


$14.3M grant to deliver affordable measles & rubella vaccines

Grant from the Bill & Melinda Gates Foundation will support Univercells and partner Batavia Biosciences to develop a cost-effective manufacturing process and proceed towards the successful commercialization of measles and rubella vaccines. BRUSSELS, BELGIUM – JUNE, 13 2019 Univercells announced today that it has been awarded a $14.3 million grant by the Bill & Melinda Gates…


Next-Geneneration Gene Therapy for Patients with Heart Disease

The European Union has awarded €15 million to the CardioReGenix consortium, as part of the Horizon2020 program. The research program is initiated to develop new gene therapy approaches for the treatment of heart disease. The program is coordinated by Professor Marinee Chuah from the Free University of Brussels (VUB) and includes thirteen international partners, including…


Batavia Biosciences receives $13.2M grant to accelerate market access of low-cost inactivated polio vaccine

Leiden, The Netherlands, February 25, 2019 – Batavia Biosciences announced today that it received a $13.2 million grant from the Bill & Melinda Gates Foundation to manufacture clinical-grade inactivated polio vaccine (sIPV), using its newly developed low-cost polio vaccine manufacturing process (marketed as HIP-Vax) based on the NevoLine™ manufacturing technology developed by Univercells. In 2016,…